title: [Experience with surgical treatment of prosthetic valve endocarditis].
abstract: Prosthetic valve endocarditis (PVE) is a rare but dangerous complication that may occur after the implantation. The authors retrospectively summarize their 11-year experience in treating PVE. 2357 prosthetic valve (PV) implantations were performed over 11 years at the Department of Cardiovascular Surgery, Semmelweis University, Budapest, PVE was found to be the indication for operation in 1.8% of the cases (43/2357). 43 surgical interventions were carried out on 38 patients (mean age: 52.5 yrs, male/female ratio: 25/13). Blood cultures were positive in 86% and negative in 14% of the cases. The infected PV-s were replaced emergently (14%), urgently (79%) or electively (7%). The explanted valves were aortic in 55% and mitral 45% of the cases, 63% were mechanical and 37% biological. PVE followed the primary PV implantation in less than a year in 39.5%. Infected environment during the primary PV implantation was found to be a predisposing factor for the late endocarditis episodes. The mean age of the infected and explanted aortic bioprosthetic valves was significantly higher than that of explanted mechanical valves (p < 0.05). No such difference could be found at the mitral valves. The explanted valves were replaced by mechanical (75.5%) or biological (22.5%) devices. Homograft was implanted once. Early postoperative mortality of the primary PV replacements was 10.5%) devices. Homograft was implanted once. Early postoperative mortality of the primary PV replacements was 10.5%. Endocarditis reoccurred in 20% of the cases. Means follow-up duration was 45.5 months. Two-, five- an 10-year survival were 75%, 64% and 51% respectively. In conclusion in the surgical treatment of PVE, bioprosthetic and mechanical valves are suitable alternatives as opposed to homografts and freestyle stentless valves.
authors.affiliation: Altalános Orvostudományi Kar, Er- és Szívsebészeti Klinika, Semmelweis Egyetem, Budapest.
authors.forename: Z
authors.initials: Z
authors.lastname: Szabolcs
authors.forename: E
authors.initials: E
authors.lastname: Bartha
authors.forename: L
authors.initials: L
authors.lastname: Gellér
authors.forename: I
authors.initials: I
authors.lastname: Hartyánszky
authors.forename: C
authors.initials: C
authors.lastname: Minorics
authors.forename: E
authors.initials: E
authors.lastname: Moravcsik
authors.forename: T
authors.initials: T
authors.lastname: Hüttl
authors.forename: T
authors.initials: T
authors.lastname: Szabó
authors.forename: E
authors.initials: E
authors.lastname: Bodor
mesh_terms: D001672:Biocompatible Materials; D001705:Bioprosthesis; D017558:Elective Surgical Procedures; D004638:Emergency Treatment; D004697:Endocarditis, Bacterial / Q000209:etiology / Q000401:mortality / Q000601:surgery*; D005260:Female; D006350:Heart Valve Prosthesis; D006801:Humans; D008297:Male; D008875:Middle Aged; D016459:Prosthesis-Related Infections / Q000401:mortality / Q000601:surgery*; D012189:Retrospective Studies; D012307:Risk Factors; D016019:Survival Analysis; D014183:Transplantation, Heterologous; D014184:Transplantation, Homologous; D016896:Treatment Outcome
chemical_list: D001672:Biocompatible Materials
vernacular_title: Múbillentyú-endocarditis sebészi kezelésével szerzett tapasztalataink.